Get the Stockscreener App
23.03
2.04%
-0.48
After Hours:
23.03
Veracyte Inc stock is traded at $23.03, with a volume of 753.08K.
It is down -2.04% in the last 24 hours and down -12.73% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$23.51
Open:
$23.66
24h Volume:
753.08K
Relative Volume:
0.77
Market Cap:
$1.80B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-30.71
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-13.58%
1M Performance:
-12.73%
6M Performance:
-47.18%
1Y Performance:
-0.65%
1-Day Range:
$22.96
$23.79
1-Week Range:
$22.61
$27.10
52-Week Range:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
23.03 | 2.09B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
What analysts say about Veracyte Inc. stockUnrivaled growth potential - jammulinksnews.com
What drives Veracyte Inc. stock priceExceptional stock performance - Autocar Professional
Are Veracyte, Inc.'s (NASDAQ:VCYT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - simplywall.st
Is Veracyte Inc. a good long term investmentHigh-margin investment plays - Autocar Professional
Veracyte Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - jammulinksnews.com
Principal Financial Group Inc. Raises Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
When is the best time to buy Veracyte Inc. stockMinimized Risk Maximum Return - Newser
Will Veracyte Inc. stock split in the near futureBreakout Momentum Stocks - Newser
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 - Lelezard
Should You Continue to Hold Veracyte Stock in Your Portfolio Now? - Nasdaq
How Veracyte Inc. stock performs during market volatility5x Profit Potential - Newser
Why Veracyte Inc. stock attracts strong analyst attentionReal Chart Play - Newser
What makes Veracyte Inc. stock price move sharplyTop Performer Shortlist - Newser
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of Texas - Defense World
Allspring Global Investments Holdings LLC Purchases 4,792 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - BioSpace
Veracyte's Afirma GRID Studies at ENDO 2025: A Paradigm Shift in Thyroid Cancer Diagnostics and Personalized Medicine - AInvest
Veracyte, Inc. Announces Multiple Afirma Grid Studies Will Be Presented At Endo 2025 - MarketScreener
Veracyte's Afirma GRID: Pioneering Precision Oncology and Driving Sustainable Growth - AInvest
Wealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time By Investing.com - Investing.com South Africa
Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time - Investing.com Canada
Veracyte's Russell 2000 Growth Index Inclusion: A Catalyst for Liquidity and Institutional Momentum - AInvest
Veracyte: A Hidden Gem in Precision Diagnostics Amid Index Exclusion - AInvest
Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold - Defense World
Veracyte exploring external buyers for divestiture of French unit’s activities - TipRanks
GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte shareholders approve 2.5 million share increase to equity plan - Investing.com
Veracyte shareholders approve 2.5 million share increase to equity plan By Investing.com - Investing.com India
Insider Sell: Karin Eastham Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Recent 3.7% Pullback Isn't Enough to Hurt Long-term Veracyte (NASDAQ:VCYT) Shareholders, They're Still up 56% Over 3 Years - 富途牛牛
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business - simplywall.st
Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability - Insider Monkey
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):